System Biosciences

Executive Summary

System Biosciences (SBI) is a leading provider of tools and services for molecular and cell biology research, with a strong focus on exosome research, CRISPR/Cas9 genome editing, gene expression systems, and liquid biopsy. Founded in 2002 and headquartered in Palo Alto, California, SBI serves academic, biotech, and pharmaceutical customers worldwide. The company's product portfolio includes exosome isolation kits, CRISPR vectors, and custom gene editing services, positioning it as a key enabler in rapidly growing areas such as exosome-based diagnostics and therapeutic development. With a long track record of innovation, SBI benefits from increasing demand for advanced research tools, particularly in liquid biopsy and gene therapy applications. Looking ahead, SBI is well-positioned to capitalize on the expanding exosome and CRISPR markets, driven by rising investment in extracellular vesicle research and the ongoing translation of gene editing therapies. The company's consistent focus on providing high-quality, reproducible products supports strong customer loyalty and recurring revenue. While SBI operates in a competitive landscape, its specialized expertise and comprehensive offerings provide a competitive edge. The company's private status limits visibility into financials, but its established presence and growth-oriented strategy suggest potential for continued expansion, possibly through strategic partnerships or new product launches.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation exosome isolation kit for liquid biopsy applications80% success
• Q4 2026Strategic partnership for CRISPR delivery system with a gene therapy developer60% success
• Q2 2026Expansion of custom gene editing services to include new cell types75% success